Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) resulted in continued virological suppression and improvement in lipoatrophy through 2 years in HIV-infected patients

被引：0

作者：

Madruga, J. V. R.

Cassetti, I.

Suleiman, J. M. A. H.

Zhong, L.

Enejosa, J.

Cheng, A. K.

机构：

[1] Ctr Reference Treinamento DST AIDS, Sao Paulo, 94404, Brazil

[2] Fdn Ctr Estudios Infectol, Buenos Aires, DF, Argentina

[3] Brasilmed Assistencia Med Res, Sao Paulo, Brazil

[4] Gilead Sci Inc, Foster City, CA USA

来源：

ANTIVIRAL THERAPY | 2006年 / 11卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：L21 / L21

页数：1

共 6 条

[1] Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from study 903E
Zhong, L
Cotton, G
Enejosa, J
Cheng, AK
ANTIVIRAL THERAPY, 2005, 10 (08) : L40 - L40
[2] Baseline genotypic analysis of treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV)
Miller, MD
Margot, NA
Waters, JM
Harris, J
Lu, B
Cheng, AK
ANTIVIRAL THERAPY, 2004, 9 (04) : U118 - U118
[3] Resistance analyses of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF (TDF) or Stavudine (d4T) with lamivudine (3TC) and efavirenz (EFV)
McColl, DJ
Margot, NA
Tran, S
Coakley, DF
Cheng, AK
Miller, MD
ANTIVIRAL RESEARCH, 2003, 57 (03) : A40 - A40
[4] THE SAFETY AND EFFICACY OF TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAIVE PATIENTS THROUGH SEVEN YEARS
Carlevari, M.
Cassetti, I.
Madruga, J. V. R.
Etzel, A.
Suleiman, J.
Zhou, Y.
Cheng, A. K.
Enejosa, J.
INFECTION, 2009, 37 : 59 - 59
[5] The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients
Cassetti, I.
Madruga, J. V. R.
Suleiman, J. M. A. H.
Zhong, L.
Enejosa, J.
Cheng, A. K.
ANTIVIRAL THERAPY, 2006, 11 (07) : L50 - L51
[6] Review of fasting lipid data from the direct study: Multicenter, open-label, 24-wk pilot with a 24-wk extension to evaluate indinavir (IDV)-ritonavir (RTV) 800/100 BID in combination with D4T & 3TC in HIV-infected individuals. (MERCK 094)
Schranz, JA
Wilson, HM
Jensen, E
Rawlins, S
Palmisano, J
CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1203 - 1203

← 1 →